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SUMMARY 
Diversamente dall'adenocarcinoma polmonare, per il carcinoma polmonare a 
cellule squamose (SQLC) non sono ancora disponibili terapie a bersaglio 
molecolare, sebbene una serie di vie di segnale sia risultata costantemente alterata. 
A questo proposito, è necessario chiarire l'eventuale impatto prognostico e/o 
predittivo dei potenziali drivers, al fine di studiare il background molecolare dei 
pazienti con SQLC. Una delle principali strategie di ricerca emergenti in ambito 
oncologico si basa sullo studio del genoma di pazienti con risposta anomala al 
trattamento o con prognosi inattesa. Adottando questa idea, abbiamo analizzato 
retrospettivamente una serie multicentrica di 573 pazienti affetti da SQLC 
sottoposti a resezione chirurgica e abbiamo costruito uno dei primi modelli di 
classificazione del rischio per SQLC, successivamente convalidato in una coorte 
più ampia di oltre 1000 pazienti. Questo modello, basato su una combinazione di 
parametri semplici clinico-patologici, è stato in grado di stratificare in modo 
efficace i pazienti con SQLC con una buona accuratezza prognostica. Una volta 
identificati i ‘migliori’ e ‘peggiori’ dal punto di vista prognostico, abbiamo studiato 
il loro ritratto molecolare, principalmente mediante sequenziamento (NGS), e il 
loro profilo di espressione per identificare alterazioni molecolari ricorrenti ed 
esplorare la loro associazione prognostica. Sessanta e quarantasette pazienti sono 
stati rispettivamente valutati come coorte di training e validazione. La variazione 
del numero di copie (CNV) era l'evento genomico più frequente. Le alterazioni 
molecolari erano distribuite indipendentemente dalla prognosi, ad eccezione delle 
mutazioni di DDR2 nel gruppo con buona prognosi e la perdita di SMAD4 nel 
gruppo con prognosi sfavorevole. L'asse PI3KCA/mTOR rappresentava la via di 
segnale più frequentemente alterata (42%) e le mutazioni di PI3KCA e l'alto CNV 
di RICTOR sono stati identificati solo nel sottogruppo a prognosi sfavorevole. 
All'analisi del trascrittoma, i pazienti con alto CNV di RICTOR avevano una 
maggiore attivazione della via di segnale PI3KCA/mTOR. Lo scopo ultimo del 
progetto era di valutare il profilo molecolare degli SQLC resecabili utilizzando 
tecnologie moderne al fine di identificare quelle aberrazioni molecolari 
potenzialmente in grado di prevedere la probabilità di recidiva e l'efficacia di agenti 
a bersaglio molecolare. Questa analisi integrata e multi-step eseguita in quasi un 
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centinaio di pazienti SQLC resecati ha identificato vie di segnale alterate con un 
impatto biologico rilevante sull’oncogenesi di SQLC, rivelando l’elevato CNV di 
RICTOR come bersaglio terapeutico candidato all'inibizione selettiva in SQLC. 
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ABSTRACT 
Differently from lung adenocarcinoma, effective targeted therapies for lung 
squamous-cell cancer (SQLC) are still missing, although a series of molecular 
pathways are constantly altered. In this regard, the prognostic and/or predictive 
impact of potential drivers needs to be elucidated, in order to create a global portrait 
of SQLC patients. Nowadays, one of the main emerging research strategies in 
cancer is centered on the study of the genome of exceptional responder and 
prognostic outlier patients. Adopting this idea, we retrospectively analysed a 
multicenter series of 573 surgically resected SQLC patients and we built one of the 
first risk classification model for SQLC, which was afterwards validated in a larger 
cohort of more than 1000 patients. This model, based on a combination of simple 
and easily available clinicopathological parameters, was able to effectively stratify 
resected SQLC patients in risk classes with a good prognostic accuracy. Once 
identified the best and worst prognostic performers, we investigated their molecular 
portrait, principally by next-generation sequencing (NGS), and their expression 
profile to identify recurrent molecular alterations and explore their association with 
prognosis. Sixty and forty-seven patients were evaluated as training and validation 
cohort, respectively. Copy number variation (CNV) was the most frequent genomic 
event. Molecular alterations were distributed regardless of prognosis, except from 
DDR2 mutations in good prognosis group and SMAD4 loss in poor prognosis group. 
The potentially druggable PI3KCA/mTOR axis represented the most frequently 
altered pathway (42%), with PI3KCA mutations and RICTOR high gain reported 
only in poor prognosis group. Upon transcriptome analysis, RICTOR high gain 
patients presented an increased pathway activity. The final aim of the overall project 
was to evaluate the molecular profile of outliers resected SQLC taking the 
advantage to adopt modern technologies in order to identify those molecular 
aberrations potentially able to predict the probability of disease recurrence and the 
efficacy of agents selectively targeting these candidate pathways. This integrated 
multi-step analysis performed in almost one hundred resected SQLC patients 
identified altered pathways with a biological impact in SQLC oncogenesis, 
revealing RICTOR high gain as a candidate therapeutical target for selective 
inhibition in SQLC.    
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INTRODUCTION 
In recent years, the identification of targetable oncogenic drivers, together with the 
introduction in clinical practice of a therapeutic decision-making process including 
tumor genotyping, provided the proof-of-principle that non-small-cell lung cancer 
(NSCLC) is composed by a group of heterogeneous diseases, which require a 
personalized approach [1]. Particularly in the context of adenocarcinoma, reliable 
evidence are available suggesting that cancer development and progression may be 
addicted through aberrant pathways specifically triggered by genetic abnormalities, 
constitutively acting as oncogenic drivers. Emblematic examples of such 
dependency are represented by EGFR mutant [2-4] and ALK rearranged 
adenocarcinoma [5, 6], where the treatment with their specific tyrosine kinase 
inhibitors significantly change the disease natural history.  
Nevertheless, epidemiologically relevant subtypes of NSCLC, as squamous-cell 
lung cancer (SQLC, approximately 25-30% of NSCLC), still lack of a reliable 
clinico-pathological and molecular characterization, in order to both stratify 
patients according to their prognosis and predict their potential susceptibility to 
targeted therapy. Regarding candidate clinico-pathological factors, the TNM stage 
represents the most reliable prognostic predictor in NSCLC patients [7]. In addition 
to TNM staging, the prognostic significance of the predominant histologic patterns 
has been validated in lung adenocarcinoma, whereas a similar prognostic role has 
been observed for histological subtyping of SQLC (i.e. keratinizing, non-
keratinizing, basaloid and clear cell subtypes) [8, 9]. However, in this uncertain 
landscape, several investigated pathological factors (including single cell invasion, 
tumor budding, nuclear diameter, number of metastatic lymph nodes, 
lymphatic/vascular and pleural invasion) demonstrated a potential prognostic role 
in different series of resected SQLC, retrospectively analyzed [8-10].    
With regard to molecular abnormalities, the Cancer Genome Atlas Research Project 
published the largest genomic characterization of SQLC, providing a 
comprehensive landscape of genomic and epigenomic alterations featuring the early 
stage of the disease. This study validated the existence of potentially druggable 
genes or pathways and provided the first evidence of the mutual exclusivity of 
genomic alterations, some of which potentially targetable by investigational agents 
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[10]. Nevertheless, only few clinical trials are ongoing to advance the development 
of targeted therapies in SQLC [11]. Recently, the therapeutic opportunities for lung 
cancer patients have further expanded with the introduction of immunotherapy, 
particularly in those tumors that feature a strong genetic diversity, such as SQLC 
[12]. Although the overexpression of programmed death-ligand 1 (PD-L1) seems 
to increase the chance to respond to immune checkpoint inhibitors in the advanced 
disease setting, its prognostic role is still debatable [13].  
In this rapidly evolving landscape, the identification of the appropriate risk category 
for each patient represents a promising strategy for two main reasons [14]. First, in 
the context of an early stage disease, the prognostic stratification might allow 
selection of those patients with a more favorable risk-benefit ratio from adjuvant 
treatments. Second, from an exploratory point-of-view, the molecular 
characterization of patients featured by a different prognosis, by applying the 
modern technologies, could help in the identification of those genomic and 
epigenomic aberrations potentially able to predict the probability of disease 
recurrence (prognostic factors) and the efficacy of agents selectively targeting these 
candidate pathways (predictive factors). Applying this research strategy in the field 
of lung cancer, we aim to create a prognostic nomogram for resected SQLC based 
on clinicopathological and molecular biomarkers, which may directly determine 
patient predictions, risk stratification and treatment assignment with targeted 
agents, according to the emerged findings in the preclinical setting. This strategy, 
may thus successfully integrate the known clinical with the newest genetic 
acquisitions into prognostic (and hopefully) predictive nomograms.  
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MATERIAL AND METHODS 
The overall project included three main steps: 
1. Building of a clinical risk classification model for resected SQLC. 
2. Validation of this clinical classification model in the context of an external 
cohort of resected SQLC.  
3. Analysis of the molecular portrait of prognostic outlier patients in order to 
identify differentially expressed and potentially druggable molecular 
targets. 
Building of a clinical risk classification model for resected SQLC. 
A step-by-step protocol was followed according to the methodological approach for 
building a nomogram for cancer prognosis proposed by Iasonos et al. [15], with 
respect to the Reporting Recommendations for Tumor Marker Prognostic Studies 
(REMARK) criteria for the conduction of a retrospective study in the context of an 
unselected population [16, 17].  
Patients’ population. 
Resected SQLC cases with stored tissue available for biomolecular analyses and at 
least 2 years follow-up, who underwent surgery since 2009 in five Italian 
institutions (University of Verona; Regina Elena National Cancer Institute, Rome; 
University of Torino; University of Perugia; University-Foundation of Chieti), were 
considered eligible. A merged database of data was accomplished. Pathological 
diagnosis was made according to the World Health Organization (WHO) 
classification and the American Joint Committee on Cancer (AJCC); the Union for 
International Cancer Control (UICC) TNM system (7th edition) for lung cancer was 
applied for disease staging.  
Endpoints.  
The aim of this first part of the analysis was to develop and validate a clinico-
pathological prognostic risk-class model to identify the best and worst performers 
in the context of a multicenter population of resected SQLC. The model was 
developed on the basis of a multivariate analysis exploring the independent impact 
of clinico-pathological factors on Overall Survival (OS: time between diagnosis and 
death for any cause), Cancer Specific Survival (CSS: time between diagnosis and 
death due to cancer progression) and Disease Free Survival (DFS: time between 
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diagnosis and local/distant recurrence, onset of secondary cancer or death for any 
cause).  
Statistical analysis.  
Descriptive statistics was used to summarize pertinent study information. Follow-
up was analyzed and reported according to Shuster et al. [18]. Associations between 
variables were analysed according to the Pearson Chi-Square test. The Hazard Ratio 
(HR) and the 95% confidence intervals (95% CI) was estimated using the Cox 
univariate model [19]. A multivariate proportional hazard model was developed 
using stepwise regression (forward selection, enter limit and remove limit p=0.10 
and p=0.15, respectively), in order to identify independent predictors of outcomes. 
The assessment of interactions between significant investigational variables was 
taken into account when developing the multivariate model. In presence of non-
linear distribution of ratios of continuous variables, the receiver operating 
characteristic (ROC) curve analysis was adopted for dichotomization according to 
outcome [20, 21]. The ROC curve analysis allowed to estimate the area under the 
curve (AUC) with standard error (SE) and 95% confidence interval, in order to 
provide a list of sensitivity, specificity, likelihood ratios, and positive and negative 
predictive values for all possible threshold values, and to calculate the difference 
between the areas under the ROC curves, with standard error, 95% confidence 
interval and P-value [22]. OS, CSS and DFS were calculated by the Kaplan-Meier 
product limit method from the date of the surgery until relapse, death due to cancer 
and/or death for any cause. Curves were reported for those prognostic factors which 
resulted independent at the multivariate analysis. The log-rank test was used to 
assess differences between subgroups. Significance was defined at the p<0.05 level. 
The SPSS®(18.0), R® (2.6.1), and MedCalc® (14.2.1) licenced statistical 
programs were used for all analyses. 
Prognostic score assessment.  
The log-HR obtained from the Cox model was used to derive weighting factors of 
a continuous prognostic index, aimed to identify differential outcomes’ risks. 
Coefficients estimates were ‘normalized’ dividing by the smallest one and rounding 
the resulting ratios to the nearest integer value [23]. Thus, a continuous score 
assigning to patients an ‘individualized’ risk was generated. Two different methods 
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were adopted to derive risk classes [24]:  
(i) for Model A, the score was dichotomized according to prognosis with 
the ROC analysis (the best ‘splitter’ cutoff is determined) [21];  
(ii) for Model B, patients’ outcomes (OS, CSS and DFS) were displayed by 
dividing patients into three risk classes, by considering cutoffs chosen 
at approximately equal distance along the range of values [23].  
Internal validation analysis.  
In order to address the multivariate model overfit and to validate the results, a cross-
validation technique, which evaluates the replication stability of the final Cox 
multivariate model in predicting all outcomes was also investigated, using a re-
sampling procedure [15, 25, 26]. This technique generates a number of simulation 
datasets (at least 100, each approximately 80% of the original size), by randomly 
selecting patients from the original sample, in order to establish the consistency of 
the model across less-powered patient’ samples. Risk classes was generated based 
on the combination of the found risk factors. The ROC analysis allowed to assess 
the predictive accuracy of the prognostic model, by the area under the curve (AUC) 
determination [22].  
The Harrell’s guidelines for the identification of the correct number of covariates 
were taken into account for the power analysis (the number of deaths should have 
be more than 10 times greater than the number of investigated predictors, so that 
the expected error from the Cox model would be less than 10%) [27]. 
Validation of this clinical classification model in the context of an external 
cohort of resected SQLC.  
Patients’ population. 
Patients with resected SQLC who had stored tissue available for pathological 
analysis and at least 2 years of follow-up after removal of the primary tumor and 
who had undergone surgery from January 2002 to December 2012 in six Italian 
institutions were considered eligible. A merged database was created. The 
pathological diagnosis was made according to the WHO classification and the 
American Joint Committee on Cancer [28]. To be consistent with the previously 
published prognostic model, the Union for International Cancer Control TNM 
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staging system (seventh edition) for lung cancer was applied for disease staging 
[29]. 
Endpoints.  
The main aim of the second part of the project was to validate the already-published 
clinical risk classification model in a larger multicenter series of patients. Moreover, 
we aimed to analyse the impact of adjuvant and neoadjuvant treatment (ANT) in 
patients with resected SQLC both in the overall cohort and in the different risk 
classes stratified according to the prognostic model.  
Statistical analysis. 
Descriptive statistics were used to summarize pertinent study information. The 
reverse method was applied to calculate the median follow-up [30]. Associations 
between variables were analyzed according to the Pearson chi-square test for 
categorical variables and the t-test for continuous variables. The HR and the 95% 
CIs were estimated by using the Cox univariate model. Each patient was assigned 
a score to classify individual risk of disease recurrence on the basis of those 
clinicopathological factors included in the published prognostic model: age (≤68 
versus >68 years), T descriptor according to seventh edition of the TNM 
classification (1 or 2 versus 3 or 4), lymph node status (negative versus positive) 
and grading (1 or 2 versus 3). Kaplan-Meier analysis for DFS, CSS, and OS was 
performed according to the three-class risk model B (with low risk equal to a score 
of 0–2, intermediate risk equal to a score of 3–4, and high risk equal to a score of 
5–6).8 The log-rank test was adopted to compare the survival curves. The Harrell’s 
C-statistic was adopted to measure the predictive accuracy of the risk model [27]. 
The effect of ANT was adjusted with the propensity score (PS) by applying the 
method of nearest neighbor matching within a specified caliper distance. In this 
regard, the PS match creates groups of patients with a similar probability of 
receiving the treatment on the basis of their baseline characteristics to minimize the 
differences in patients’ covariates, which could become confounding factors in the 
examination of treatment effects in a nonrandomized cohort [31]. Specifically, a PS 
for the likelihood of receiving ANT was calculated by using a covariate adjustment 
method including a series of clinicopathological factors that might influence 
doctors’ choice about treatment: age, T descriptor according to seventh edition of 
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the TNM classification, lymph node status, and grading. According to these 
covariates, an unmatched sample of patients was identified. By using a 1:1 nearest 
neighbor matching algorithm that pairs patients with the closest PS within a defined 
limit (calipers of width equal to 0.2), the PS yielded two well-matched patient 
cohorts (logistic regression estimation algorithm). Significance was defined at the 
p<0.05 level. The SPSS®(18.0), R® (2.6.1), and MedCalc® (14.2.1) licenced 
statistical programs were used for all analyses. 
Analysis of the molecular portrait of prognostic outlier patients. 
Patients. 
Resected SQLC patients with available formalin-fixed paraffin embedded (FFPE) 
blocks for molecular analysis with at least 2 years of follow-up after removal of the 
primary tumor, who underwent surgery since 2009 in three Italian institutions 
(University of Verona, Regina Elena National Cancer Institute - Rome, University 
of Turin provided data for the training set) and classified as good prognosis (GP) or 
poor prognosis (PP) in terms of DFS according to the previously built and validated 
three-class prognostic model, were considered eligible. University of Perugia 
provided an additional cohort of resected SQLC samples to be available as a 
validation set.  
Somatic mutations (SM) and copy number variations (CNV) analysis by next-
generation sequencing (NGS) on tumor samples. 
DNA was obtained from matched tumor and non-neoplastic lung included in 
formalin-fixed paraffin embedded (FFPE) blocks. In particular, tumor DNA from 
FFPE was prepared after enrichment for neoplastic cellularity to at least 70% using 
manual microdissection of 10 consecutive 4-μm FFPE sections. Sections were then 
purified using the QIAamp DNA FFPE Tissue Kit (Qiagen) and qualified. A Tissue 
Macro Array (TMA) was built including all cases (three cores each ones) and three 
normal lung as control. Matched tumor/normal DNA from all FFPE samples was 
subjected to targeted NGS. The Comprehensive Cancer panel (CCP) was used to 
investigate the mutational status of 409 genes in training set (details on target 
regions of the commercial panel are at http://www.thermofisher.com). Tumor 
Mutational Burden (TMB) was estimated according to Rizvi et al. [32]. Briefly, 
number of somatic mutations identified in each sample is divided by the number of 
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base pair covered by CCP for a genomic space of 1.7Mb. Regarding the mutational 
analysis of validation set, a custom panel targeting 56 genes was selected upon the 
results from the discovery screen using CCP, and published exome and targeted 
sequencing studies [10, 33, 34]: AKT1, ALK, APC, ARID1A, ARID2, ATM, BAP1, 
BCL2L1, CCND1, CCND2, CDH1, CDH10, CDKN2A, CHD7, CUL3, DDR2, 
EGFR, ERBB2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, FRS2, KAT6A, KDM6A, 
KEAP1, KMT2D, KRAS, MDM2, MET, MYC, MYCL, NF1, NFE2L2, NOTCH1, 
NOTCH2, NOTCH3, NRAS, PAPPA2, PIK3CA, PTEN, RASA1, RB1, RICTOR, 
SMAD4, SMARCA4, SOX2, STAT3, TERT, TET2, TIE1, TP53, TP63, TSC1 and 
TSC2. Regarding CNV analysis of cell lines, a custom panel targets selected regions 
of 36 genes selected upon the results of published whole genome sequencing and 
exome data [33, 34]: AKT1, APC, BCL2L1, CCND1, CCND2, CDKN2A, CDKN2B, 
DDR2, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, FRS2, KIT, MDM2, MET, MYC, 
MYCL, MYCN, NFE2L2, NOTCH1, PDGFRA, PIK3CA, PTEN, RB1, RICTOR, 
SMAD4, SOX2, TERT, TET2, TIAF1, TP53, TP63, TSC2 and TUBG1. An 
orthogonal validation using FISH or qPCR was performed to confirm a subset of 
the CNVs identified. In this case, only concordant results between methodical were 
reported. In term of cut-off, CNV > 5 was defined as high gain, while CNV ≤ 5 as 
low gain.      
CNV validation by Quantitative PCR (q-PCR). 
RNA was obtained from 10 consecutive 6-μm FFPE sections using RecoverAll total 
nucleic acid isolation kit protocol (ThermoFisher). RNA was quantified using Qubit 
RNA BR Assay Kit (ThermoFisher) and qualified using Agilent RNA 6000 Nano 
Kit (Agilent Technologies). A RNA Integrity Number (RIN) over 5 was considered 
suitable for transcriptomic analysis. Quantitative PCR analysis of copy numbers 
was applied to all samples for selected loci. All target and reference assays were 
purchased from Applied Biosystems. RNaseP was used as endogenous control for 
normalization of analysed loci. The following assays were used: MTOR 
(Hs00873941), RB1 (Hs06406077), TP53 (Hs06423639), CDKN2A 
(Hs04369574),  MYC (Hs03660964), SMAD4 (Hs06491600), FGFR1 
(Hs00870416), TERT (Hs00412608), RICTOR (Hs01559952), PIK3CA 
(Hs06609754), MYCL (Hs00767289), MEN1 (Hs01778293), PTEN 
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(Hs05217581), CCND1 (Hs03772544), MET (Hs04951661), AKT1 (Hs2893205), 
FHIT (Hs03491211), SRC (Hs07169853) and RNaseP (part number 4403326). The 
experimental procedure recommended by the manufacturer (Applied Biosystems) 
was followed.  
Fluorescent in situ hybridization (FISH) analysis on tumor samples. 
A FISH analysis was developed according manufacturer instruction to validate 
CNV obtained by NGS analysis for the following genes: MYC, MDM2, ERBB2, 
CDKN2A, MET, TP53 and PTEN (all probes Vysis/Abbott Molecular) and 
RICTOR (Empire Genomics). Protocol, data analysis and interpretation were 
performed as previously reported [35, 36].  
Western blotting and antibodies. 
Immunoblotting was performed using the following antibodies in dilutions 
according manufacturer’s recommendations, against Akt (#9272), phosphor-
Akt(S473) (#4060), S6 (#2317), phospho-S6 (#4857), phospho-4E-BP1(#2855), β-
Actin (#4967).  
Expression analysis for genes of PI3K/mTOR pathway. 
The Ion AmpliSeq Transcriptome Human Gene Expression Kit (Thermo Fisher) 
was used to analyse the expression levels of genes belonging to PI3K/mTOR 
family. To evaluate a potential correlation between RICTOR gene dosage and 
transcriptional output of PI3K/mTOR pathway, we applied a previously defined 
PI3K/mTOR transcriptional signature [37] and available dataset from MSigDB, 
which are based on genes that are modulated by PI3K inhibitors or involved in 
negative regulation of the pathway, respectively. 
Statistical analysis. 
Descriptive statistic was used to summarize pertinent study information. One-way 
ANOVA, Kruskal-Wallis test, Fisher's test with Monte Carlo simulation, and 
Fisher’s exact test corrected for multiple comparisons were used as appropriate. The 
inter-rater variability and agreement between frequencies of both SM and CNV in 
training set and validation set was analyzed according to the Kappa (k) index. The 
index was interpreted according to the following values: <0.20 (bad); 0.21-0.40 
(poor); 0.41-0.60 (moderate); 0.61-0.80 (good); and 0.81-1.00 (excellent) [38]. 
Correlation analysis between SM and CNV frequencies in training set and 
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validation set was also conducted, according to parametric (Pearson's r, with 95% 
confidence intervals, CI) and non-parametric (Spearman's Rho and Kendall's Tau) 
coefficients; a regression equation/line was calculated according to the regression 
analysis (parametric R2) [39]. In order to visually test and weigh differences 
between SM and CNV frequencies in training set and validation set, the Bland-
Altman plots were determined [40]. For all the analyses, significance was defined 
at the p<0.05 level. The SPSS (v. 18.0), R (v. 3.2.1 and survival library v.2.38-2 for 
multivariate Cox regression) and MedCalc (v. 15.6) licensed statistical programs 
were used for all analyses. 
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RESULTS 
Building of a clinical risk classification model for resected SQLC. 
Patients.  
Data from 573 patients from five different Italian institutions were gathered. Four 
hundred ninety-four patients were evaluable for the clinical analysis, with an 
attrition rate of 13.7%. Median age was 68 years (range: 32-83 years); the median 
number of resected nodes was 13 (range: 1-62). Overall patients’ characteristics are 
shown in Table 1.   
Table 1. Patients’ characteristics (494 evaluable patients for the clinical analysis). 
 
  
 Patients Number (%) 
Gender  
Male  403 (81.6) 
Female 91 (18.4) 
T descriptor according to TNM 7th edition    
1 132 (26.7) 
2 227 (46.0) 
3 106 (21.6) 
4 29 (5.7) 
TNM staging  
I 259 (52.4) 
II 118 (23.9) 
III 102 (19.4) 
IV 15 (2.4) 
Lymph nodes   
Negative 339 (68.6) 
Positive 155 (31.4) 
Resected lymph nodes   
< 10 133 (26.9) 
≥ 10 361 (73.1) 
N status  
(N descriptor according to TNM 7th edition) 
 
0 339 (68.6) 
1 65 (13.2) 
2 63 (12.8) 
3 27 (5.4) 
Grading   
G 1-2 219 (44.3) 
G 3 177 (35.9) 
Unknown 98 (19.8) 
Chemotherapy  
Neoadjuvant 26 (5.2) 
Adjuvant 75 (15.2) 
None 272 (55.1) 
Unknown 121 (24.5) 
Surgery  
Lobectomy 308 (62.3) 
Bi-lobectomy 45 (9.1) 
Pneumonectomy 74 (15.0) 
Unknown 67 (13.6) 
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Survival analysis.  
Median follow-up was 28 months (range: 1-213 months). The overall number of 
deaths was 202 (164 due to cancer, 38 due to other causes). Median DFS, CSS and 
OS were 38 months (95% CI 31-45), 81 months (95% CI 50-112) and 58 months 
(95% CI 42-74), with a 5-year rate of 38.6%, 55.8% and 48.6%, respectively. At the 
multivariate analysis, age ≤68 years, tumor size 1-2, negative nodes, and grading 1-
2 were significant independent predictors for longer DFS and OS. With regard to 
CSS, tumor size 1-2, negative nodes, and grading 1-2 were significant prognostic 
predictors (Table 2).   
Table 2. Multivariate survival analysis. 
 Legend - Table 2: HR, hazard ratios; CI, confidence intervals. 
Internal validation analysis.   
At the cross-validation analysis, nodes, grading, tumor size and age were confirmed 
as independent factors for DFS (replication rate: 98%, 72%, 70% and 86%, 
respectively). The same factors were confirmed to be independent predictors for OS 
at the internal validation (replication rate: 100%, 98%, 100%, and 100% for nodes, 
grading, T-descriptor, and age, respectively). For what concerns CSS, at the cross-
validation analysis nodes and T-descriptor were confirmed as independent 
predictors (replication rate: 93% and 93%, respectively). 
Variables 
DFS CSS OS 
HR 95%CI P HR 95%CI P HR 95%CI P 
Gender 
[male versus female] 
- - - - - - - - - 
Age 
[>68 versus ≤68 years] 
1.58 1.14-2.18 0.005 - - - 2.17 1.48-3.17 <0.0001 
T descriptor 
according to TNM 7th 
edition 
[3-4 versus 1-2] 
1.75 1.22-2.51 0.002 2.26 1.40-3.66 0.001 2.12 1.40-3.21 <0.0001 
Lymph nodes 
[positive versus 
negative] 
2.27 1.57-3.27 <0.0001 2.93 1.79-4.80 <0.0001 2.59 1.70-3.96 <0.0001 
Resected lymph nodes 
[<10 versus ≥10] 
- - - - - - - - - 
N status  
(N descriptor according 
to TNM 7th edition) 
[1 versus 0] 
[2-3 versus 0] 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
 
 
 
- 
Grading 
[3 versus 1-2] 
1.41 1.03-1.94 0.033 - - - 1.65 1.13-2.40 0.008 
TNM staging 
(III/IV versus I/II) 
- - - - - - - - - 
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Prognostic score and Model Performance.  
According to the HRs obtained at the multivariate analysis, a prognostic scoring 
index was assigned to each patient to identify the individual risk of recurrence 
(Table 3).  
Table 3. Prognostic score assessment according to Disease Free Survival. 
 
 
 
 
 
 
The score dichotomization according to outcome, derived from the ROC analysis 
and the maximally selected log-rank statistics, identified 2 as the optimal cutoff 
point. According to the two-class model (model A), a statistically significant 
prognostic difference between patients at low (score ≤2) and high risk (score >2) 
was determined for both DFS (3-year: 64.6% and 32.4%, p < 0.0001; 5-year: 52.5% 
and 15.1%; p < 0.0001), CSS (3-year: 84.4% and 44.5%, p < 0.0001; 5-year: 78.8% 
and 24.5%; p < 0.0001), and OS (3-year: 77.3% and 38.8%, p < 0.0001; 5-year: 
67.6% and 17.0%; p < 0.0001; Figure 1).  
On the basis of the outcome, patients were divided into three risk classes, by 
considering cutoffs chosen at approximately equal distance along the range of 
values: (1) low risk of recurrence and death: score 0-2 (the best outcome estimate); 
(2) intermediate risk of recurrence and death: score 3-4; (3) high risk of recurrence 
and death: score 5-6 (worst outcome estimate). According to the three-class model 
(model B), a highly significant prognostic difference between patients at low, 
intermediate, and high risk was found for DFS (3-year: 64.6%, 39.8%, and 21.8%, 
p < 0.0001; 5-year: 52.5%, 23.2%, and 6.2%, p < 0.0001), CSS (3-year: 84.4%, 
55.4%, and 30.9%, p < 0.0001; 5-year: 78.8%, 35.0%, and 15.5%, p < 0.0001), and 
OS (3-year: 77.3%, 47.9%, and 27.2%, p < 0.0001; 5-year: 67.6%, 25.4%, and 
9.1%, p < 0.0001; Figure 1).  
 
 
Disease Free Survival 
Score points 
0 1 2 
Age ≤68 >68 - 
T-descriptor according to TNM 
7th edition 
1-2 - 3-4 
Lymph nodes Negative - Positive 
Grading 1-2 3 - 
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Figure 1. Disease Free Survival (A and B), Cancer Specific Survival (C and D) and 
Overall Survival (E and F), according to risk classes as developed for Model A (A, 
C and E) and Model B (B, D and F). The 5-years rate for each outcome is reported. 
p, P value at long-rank analysis.   
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Validation of this clinical classification model in the context of an external 
cohort of resected SQLC.  
Patients.  
Data on 1,375 patients from six different Italian institutions were gathered. The 
patients’ median age was 68 years (range 38-90 years). As a clinical descriptor, the 
median number of resected nodes was 17 (range 1-85). Patient characteristics are 
reported in Table 4. Most of the included patients were male (86.8%) and affected 
by SQLC with a T descriptor of 1 or 2 (71.7%) versus 3 or 4 (24.9%) and stage I or 
II (71%) versus III or IV (28.0%). Nearly half of the patients (46.3%) presented 
lymph node involvement. The most frequent surgical procedure among the included 
patients was lobectomy (67.1%), followed by pneumonectomy (24.9%). Overall, 
384 patients (27.9%) were treated with adjuvant therapies, including platinum-
based doublet chemotherapy (n = 254 [18.5%]), radiotherapy (n = 94 [6.8%]), and 
chemoradiotherapy (n = 36 [2.6%]). A total of 270 patients (19.6%) received 
neoadjuvant treatments, mainly platinum-based doublet chemotherapy (n = 254 
[18.5%]), with only few cases of radiotherapy (n = 7 [0.5%]) and concomitant 
chemoradiotherapy (n = 9 [0.7%]). A total of 114 patients (8.3%) received both an 
adjuvant and a neoadjuvant treatment. According to the previously published 
prognostic model, 687 patients (50.0%) were classified as low-risk (score 0-2), 406 
(29.5%) as intermediate-risk (score 3-4), and 123 patients (8.9%) as poor-risk 
(score 5-6) patients.  
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Table 4. Patients’ characteristics (1,375 evaluable patients for the clinical analysis).  
 Patients Number (%) 
Median age (range) 68 (38-90) 
Gender  
Male  1194 (86.8) 
Female 181 (13.2) 
Tumor size  
[T descriptor according to TNM 7th edition] 
  
0 22 (1.6) 
1 300 (21.8) 
2 686 (49.9) 
3 255 (18.5) 
4 88 (6.4) 
Unknown 24 (1.7) 
TNM staging  
I 555 (40.4) 
II 421 (30.6) 
III 376 (27.3) 
IV 9 (0.7) 
Unknown 14 (1.0) 
Lymph nodes   
Negative 728 (52.9) 
Positive 636 (46.3) 
Unknown 11 (0.8) 
Resected lymph nodes   
< 10 272 (19.8) 
≥ 10 877 (63.8) 
Unknown 226 (16.4) 
N status  
[N descriptor according to TNM 7th edition] 
 
0 728 (52.9) 
1 408 (29.7) 
2 227 (16.5) 
3 1 (0.1) 
Unknown 11 (0.8) 
Grading   
1-2 481 (35.0) 
3 565 (41.1) 
Unknown 329 (23.9) 
Risk Class  
[according to the prognostic model] 
  
0-2 687 (50.0) 
3-4 406 (29.5) 
5-6 123 (8.9) 
Unknown 159 (11.6) 
Neoadjuvant Therapy  
No 934 (67.9) 
Chemotherapy 254 (18.5) 
Chemoradiotherapy 9 (0.7) 
Radiotherapy 7 (0.5) 
Unknown 171 (12.4) 
Surgery  
Lobectomy 923 (67.1) 
Bi-lobectomy 110 (8.0) 
Pneumonectomy 342 (24.9) 
Adjuvant Therapy  
No 728 (52.9) 
Chemotherapy 254 (18.5) 
Chemoradiotherapy 36 (2.6) 
Radiotherapy 94 (6.8) 
Unknown 263 (19.1) 
22 
 
Survival Analysis and Validation of the Prognostic Model. 
The median follow-up calculated with the reverse method was 55 months (95% CI: 
51–59). In all, 1,097 patients were evaluable for the survival analysis, with an 
attrition rate of 21.3% (the clinical or pathological descriptors for survival analysis 
were missing for 159 patients and the follow-up date was missing for 119 patients). 
According to the three-class model, patients included in the low-risk class had a 
significantly longer DFS than patients at intermediate (HR = 1.67, 95% CI: 1.40–
2.01) and high risk (HR ¼ 2.46, 95% CI: 1.90–3.19). The 5-year DFS rates for low-
, intermediate-, and high-risk patients were 51.0%, 33.5%, and 25.8%, respectively 
(p < 0.0001) (Figure 2A). In strict accordance, a statistically significant advantage 
was observed for low-risk patients versus for intermediate- and high-risk patients 
in terms of CSS (HR = 2.46, 95% CI: 1.80–3.36 versus HR = 4.30, 95% CI: 2.92–
6.33) and OS (HR = 1.79, 95% CI: 1.48–2.17 versus HR ¼ 2.33, 95% CI: 1.76–
3.07). The 5-year CSS rates for low-, intermediate-, and high-risk patients were 
82.7%, 64.7%, and 53.3%, respectively (p < 0.0001). The 5-year OS rates for low, 
intermediate and high-risk patients were 56.7%, 37.9%, and 30.9%, respectively (p 
< 0.0001) (Figure 2B and C). The C-statistic values for DFS, CSS, and OS were 
0.68 (95% CI: 0.63–0.73), 0.66 (95% CI: 0.61–0.71), and 0.68 (95% CI: 0.63–0.72), 
respectively. 
Figure 2. Disease-free survival (A), cancer-specific survival (B), and overall 
survival (C) according to the three-class risk model. The 5-year rate for each 
outcome is reported; p value at long-rank analysis. 
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PS Analysis for the Impact of ANT. 
In the entire patient cohort, no significant differences according to administration 
of ANT were observed in terms of DFS (p = 0.77 [5-year DFS 44.9% versus 
42.8%]), CSS (p = 0.11 [5-year CSS 76.2% versus 67.4%]), or OS (p = 0.16 [5-year 
OS 52.0% versus 45.9%]) when the analysis was corrected by PS (Figure 3). 
Nevertheless, when the overall population was stratified according to the three-class 
risk model, a trend in favor of ANT was observed for intermediate-risk/high-risk 
patients, particularly in terms of CSS (p = 0.06 [5-year CSS 72.7% versus 60.8%]) 
(Figure 4). In the low-risk group, no significant differences according to the 
administration of ANT were observed in terms of any survival outcome analyzed.  
Figure 3. Disease-free survival (A), cancer-specific survival (B), and overall 
survival (C) according to the administration of adjuvant and neoadjuvant treatment 
(ANT) in the overall population adjusted for propensity score analysis. The 5-year 
rate for each outcome is reported; p value at long-rank analysis. 
 
Figure 4. Disease-free survival (A), cancer-specific survival (B), and overall 
survival (C) according to the administration of adjuvant and neoadjuvant treatment 
(ANT) in the intermediate-risk/high-risk population adjusted for propensity score 
analysis. The 5-year rate for each outcome is reported; p value at long-rank analysis. 
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Analysis of the molecular portrait of prognostic outlier patients. 
Patients’ cohorts. 
We conducted sequencing analyses on 60 resected SQLC samples (training set), 27 
patients classified as GP and 33 as PP, according to the previously designed and 
validated three-class prognostic model. Training set patients’ characteristics 
according to the prognostic groups are reported in Table 5.  
Table 5. Clinical and pathological characteristics of the 60 patients included in the 
training set, separated in prognostic groups (PP and GP) according to the previously 
published three-class prognostic model. 
Training Set 
PP 
(N = 33) 
GP 
(N = 27) 
Patient number (%) 
Median age [years] 
Range 
74 
[67 - 82] 
63 
[43 - 72] 
Gender   
Male  28 (84.8) 20 (74.0) 
Female 5 (15.2) 7 (26.0) 
TNM Staging  
[according to TNM 7th edition] 
  
I 0 (0.0) 14 (51.8) 
II 0 (0.0) 13 (48.2) 
III 33 (100.0) 0 (0.0) 
Lymph nodes    
Negative 0 (0.0) 27 (100.0) 
Positive 33 (100.0) 0 (0.0) 
Tumor size  
[T descriptor according to  
TNM 7th edition] 
  
1 0 (0.0) 10 (33.3) 
2 0 (0.0) 15 (59.3) 
3 30 (78.8) 2 (7.4) 
4 3 (21.2) 0 (0.0) 
Node status 
[N descriptor according to 
TNM 7th edition] 
  
0 0 (0.0) 27 (100.0) 
1 22 (36.4) 0 (0.0) 
2 9 (51.5) 0 (0.0) 
3 2 (12.1) 0 (0.0) 
Grading   
1 0 (0.0) 3 (11.1) 
2 5 (15.2) 20 (74.1) 
3 28 (84.8) 4 (14.8) 
Legend - Table 5. PP, poor prognosis; GP, good prognosis; N, number; NR, not 
reach. 
An additional cohort of 37 specimens from resected SQLC patients, collected 
regardless of prognosis, was available as validation set from University of Perugia.  
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Molecular features.   
In the training set, somatic mutations were detected in 59 cases in 38 genes (Figure 
5A, Table 6). In detail, one mutation was observed in 9/60 cases (15.0%), more than 
one in 50/60 (83.3%) cases, while no alteration in only one case (1.7%). The most 
commonly mutated genes in the whole cohort was TP53 (53/60; 88.3%) and 
KMT2D (10/60; 16.7%). CNV were observed in all cases in 40 genes (Figure 5B, 
Table 7]. In detail, one CNV was observed in 3/60 cases (5.0%), more than one in 
57/60 cases (95.0%). CNV analysis showed copy number gain of SOX2 (47/60; 
78.3%) as the most frequent event, followed by gain in PIK3CA (34/60; 56.7%) and 
TP63 (24/60; 40.0%). Of note, RICTOR gain was present in 14/60 samples (23.3%).  
An additional cohort of 37 resected SQLC samples was used to validate the 
molecular analysis results of the training set (Figure 5A-B).  
Figure 5: Comparison of somatic mutations [A] and copy number variation [B] 
between training and validation set.  
 
Legend - Figure 5: CNV, copy number variation; LOH, loss of heterozygosity. 
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Table 6. Prevalence of somatic mutations [SM] in 38 altered genes in 60 resected 
SQLC samples (training set) according to the prognostic groups (PP and GP). 
Gene 
PP  
N (%) 
GP 
N (%) 
Total  
N (%) 
p-value* 
ALK 1 (3.0) 1 (3.7) 2 (3.3) - 
APC 0 (0.0) 1 (3.7) 1 (1.7) - 
ARID1A 1 (3.0) 1 (3.7) 2 (3.3) - 
ARID2 0 (0.0) 1 (3.7) 1 (1.7) - 
ATM 1 (3.0) 1 (3.7) 2 (3.3) - 
BAP1 1 (3.0) 2 (7.4) 3 (5.0) - 
CDH1 1 (3.0) 3 (11.1) 4 (6.7) - 
CDH10 1 (3.0) 4 (14.8) 5 (8.3) - 
CDKN2A 1 (3.0) 3 (11.1) 4 (6.7) - 
CHD7 1 (3.0) 1 (3.7) 2 (3.3) - 
CUL3 0 (0.0) 2 (7.4) 2 (3.3) - 
DDR2 0 (0.0) 3 (11.1) 3 (5.0) - 
EGFR 1 (3.0) 0 (0.0) 1 (1.7) - 
FBXW7 1 (3.0) 1 (3.7) 2 (3.3) - 
FLT3 1 (3.0) 0 (0.0) 1 (1.7) - 
KAT6A 1 (3.0) 0 (0.0) 1 (1.7) - 
KDM6A 1 (3.0) 1 (3.7) 2 (3.3) - 
KEAP1 4 (12.1) 2 (7.4) 6 (10.0) - 
KMT2D 7 (21.2) 3 (11.1) 10 (16.7) - 
KRAS 1 (3.0) 2 (7.4) 3 (5.0) - 
NF1 2 (6.1) 0 (0.0) 2 (3.3) - 
NFE2L2 1 (3.0) 3 (11.1) 4 (6.7) - 
NOTCH1 0 (0.0) 2 (7.4) 2 (3.3) - 
NOTCH2 1 (3.0) 0 (0.0) 1 (1.7) - 
NOTCH3 1 (3.0) 2 (7.4) 3 (5.0) - 
NRAS 1 (3.0) 0 (0.0) 1 (1.7) - 
PAPPA2 1 (3.0) 1 (3.7) 2 (3.3) - 
PIK3CA 3 (9.1) 0 (0.0) 3 (5.0) - 
PTEN 3 (9.1) 3 (11.1) 6 (10.0) - 
RASA1 0 (0.0) 1 (3.7) 1 (1.7) - 
RB1 2 (6.1) 4 (14.8) 6 (10.0) - 
SMAD4 1 (3.0) 0 (0.0) 1 (1.7) - 
SMARCA4 1 (3.0) 0 (0.0) 1 (1.7) - 
STAT3 0 (0.0) 1 (3.7) 1 (1.7) - 
TIE1 2 (6.1) 2 (7.4) 4 (6.7) - 
TP53 28 (84.8) 25 (92.6) 53 (88.3) - 
TSC1 1 (3.0) 2 (7.4) 3 (5.0) - 
TSC2 1 (3.0) 1 (3.7) 2 (3.3) - 
 
Legend - Table 6. N, number; p-value* are reported only if <0.05 according to 
Fisher’s exact test. 
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Table 7. Prevalence of copy number variations [CNV] in 40 altered genes in 60 
resected SQLC samples (training set) according to the prognostic groups (PP and 
GP). 
Gene 
PP  
N (%) 
GP 
N (%) 
Total  
N (%) 
p-value* 
AKT1 [Gain] 3 (9.1) 2 (7.4) 5 (8.3) - 
APC [Loss] 3 (9.1) 3 (11.1) 6 (10.0) - 
BCL2L1 [Gain] 5 (15.2) 6 (22.2) 11 (18.3) - 
CCND1 [Gain] 5 (15.2) 4 (14.8) 9 (15.0) - 
CCND2 [Gain] 8 (24.2) 4 (14.8) 12 (20.0) - 
CDKN2A [Loss] 9 (27.3) 7 (25.9) 16 (26.7) - 
DDR2 [Gain] 3 (9.1) 3 (11.1) 6 (10.0) - 
EGFR [Gain] 4 (12.1) 4 (14.8) 8 (13.3) - 
ERBB2 [Gain] 5 (15.2) 3 (11.1) 8 (13.3) - 
FGFR1 [Gain] 5 (15.2) 6 (22.2) 11 (18.3) - 
FGFR2 [Gain] 3 (9.1) 4 (14.8) 7 (11.7) - 
FGFR3 [Gain] 2 (6.1) 3 (11.1) 5 (8.3) - 
FOXP1 [Loss] 7 (21.2) 10 (37.0) 17 (28.3) - 
FOXP4 [Loss] 2 (6.1) 4 (14.8) 6 (10.0) - 
FRS2 [Gain] 7 (21.2) 5 (18.5) 12 (20.0) - 
JAK3 [Gain] 6 (18.2) 6 (22.2) 12 (20.0) - 
KIT [Gain] 4 (12.1) 1 (3.7) 5 (8.3) - 
MCL1 [Gain] 9 (27.3) 5 (18.5) 14 (23.3) - 
MDM2 [Gain] 6 (18.2) 6 (22.2) 12 (20.0) - 
MET [Gain] 2 (6.1) 1 (3.7) 3 (5.0) - 
MYC [Gain] 3 (9.1) 1 (3.7) 4 (6.7) - 
MYCL1 [Gain] 2 (6.1) 2 (7.4) 4 (6.7) - 
MYCN [Gain] 2 (6.1) 2 (7.4) 4 (6.7) - 
NFE2L2 [Gain] 6 (18.2) 1 (3.7) 7 (11.7) - 
NOTCH1 [Loss] 4 (12.1) 1 (3.7) 5 (8.3) - 
PBRM1 [Loss] 7 (21.2) 7 (25.9) 14 (23.3) - 
PDGFRA [Gain] 5 (15.2) 5 (18.5) 10 (16.7) - 
PIK3CA [Gain] 18 (54.5) 16 (59.3) 34 (56.7) - 
PTCH1 [Loss] 5 (15.2) 2 (7.4) 7 (11.7) - 
PTEN [Loss] 11 (33.3) 10 (37.0) 21 (35.0) - 
RB1 [Loss] 9 (27.3) 6 (22.2) 15 (25.0) - 
RICTOR [Gain] 7 (21.2) 7 (25.9) 14 (23.3) - 
SMAD4 [Loss] 11 (33.3) 2 (7.4) 13 (21.7) 0.025 
SMARCB1 [Gain] 7 (21.2) 8 (29.6) 15 (25.0) - 
SOX2 [Gain] 24 (72.7) 23 (85.2) 47 (78.3) - 
TERT [Gain] 6 (18.2) 3 (11.1) 9 (15.0) - 
TET2 [Loss] 1 (3.0) 3 (11.1) 4 (6.7) - 
TP53 [Loss] 2 (6.1) 2 (7.4) 4 (6.7) - 
TP63 [Gain] 14 (42.4) 10 (37.0) 24 (40.0) - 
TSC2 [Gain] 1 (3.0) - 1 (1.7) - 
Legend - Table 6. N, number; p-value* are reported only if <0.05 according to 
Fisher’s exact test.  
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Comparison between the two cohorts is reported in Figure 6A-B. A substantial 
agreement for SM and CNV frequencies in training and validation set was observed, 
with a significant overall correlation between them (Figure 6C). The Bland-Altman 
plot did confirm the absence of major differences or discrepancies between SM and 
CNV frequencies in training and validation set (Figure 6D).  
Figure 6: Frequencies of somatic mutations, SM [A] and copy number variations, 
CNV [B] in training (TS) and validation set (VS). Inter-agreement weighted K, 
correlation and regression analysis SM and CNV frequencies between TS and VS 
according to Pearson, Spearman and Kendall-Thau’s tests [C]. Bland-Altman plot 
weighting differences in SM and CNV frequencies between TS and VS [differences 
plotted against TS] [D]. 
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Legend - Figure 6: TS, training set; VS, validation set; N, number; SM, somatic 
mutation; CNV, copy number variation; CI, confidence interval. 
 
In order to characterize the molecular background of SQLC prognostic outliers, we 
stratified the training cohort according to the prognostic model. A significant 
prognostic difference between patients at good and poor prognosis was found for 
disease-free survival (3-year: 42.9% and 10.4%, p=0.003), cancer-specific survival 
(3-year: 72.3% and 34.1%, p=0.02) and overall survival (3-year: 69.3% and 35.8%, 
p=0.01) (Figure 7).  
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Figure 7:  Disease-free survival, cancer-specific survival and overall survival for 
good (GP) [blue line] and poor (PP) prognosis [yellow line] groups according to the 
published risk model. The 3-year rate for each outcome is reported, p value at long-
rank analysis. 
 
Legend - Figure 7: Disease-free survival, DFS; cancer-specific survival, CSS; 
overall survival, OS. 
The prevalence of SM and CNV according to prognostic groups are reported in 
Figure 8. In 33 cases of the PP group, TP53 was the most mutated gene (28/33; 
84.8%), followed by KMT2D (7/33; 21.2%) and KEAP1 (4/33; 12.1%). 
Interestingly, PIK3CA (3/33; 9.1%) and NF1 (2/33; 6.1%) were mutated at low 
frequency, but exclusively in PP group. Regarding CNV, copy number gain in 
SOX2 (24/33; 72.7%) was the most frequent event, followed by PIK3CA gain 
(18/33; 54.5%). SMAD4 loss was particularly enriched in PP compared with GP 
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group (11/33; 33.3% versus 2/27; 7.4%, p=0.025), resulting in a statistically 
significant higher chance to be associated with poor prognosis (OR 4.491, 95% CI 
1.320 - 15.277, p=0.016) (Figure 8). In the 27 patients of the GP group, TP53 was 
the most mutated gene (25/27; 92.6%), followed by CDH10 and RB1 (4/27; 14.8%). 
DDR2 mutations were exclusively identified in GP group (3/27; 11.1%) with a 
higher possibility to be associated with good prognosis (OR 0.100, 95%CI 0.010 - 
1.014, p=0.051) (Figure 8). About CNV, GP shared with PP a similar frequency in 
term of gain in SOX2 (12/33; 36.4%), PIK3CA (16/27; 59.3%) and TP63 (10/27; 
37.0%). Other frequent events observed included FOXP1 and PTEN loss (10/27; 
37.0%).  
Figure 8. Comparison of mutational load, chromosome integrity number, somatic 
mutations and copy number variation between PP and GP. Blue columns and green 
columns represent SM and CNV, respectively. Odds Ratio analysis of somatic 
mutations and copy-number variation according to prognosis: an OR<1 indicates a 
higher chance to be associated with good prognosis; an OR>1 indicates a higher 
chance to be associated with poor prognosis.  
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Legend - Figure 8: CIN, chromosome integrity number; CNV, copy number 
variation; OR, Odds Ratio; CI, confidence interval; SM, somatic mutation.  
 
Tumor Mutational Burden (TMB) was estimated according to Rizvi et al.9 using 
the 1.7 Mb of genomic space covered by the CCP. A global median of 1.2 
mutations/Mb (1.4 mean) was achieved for all samples analyzed. In particular, in 
PP group a median of 1.2 mutations/Mb (1.2 mean) was observed, while in GP 
group a median of 1.8 mutations/Mb (1.6 mean) (Figure 9). 
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Figure 9: Tumor Mutation Burden analysis according to prognosis. 
 
 
Although no significant difference according to the prognosis emerged in term of 
alterations of the mTOR family members, PI3KCA mutations and RICTOR high 
gain amplification were detected only in PP group (Figure 10). Overall, alterations 
in genes involved in the PI3K/mTOR pathway were detected in 42% of the analysed 
samples. 
 
Figure 10. Prevalence of mTOR pathways alterations in GP and PP groups. 
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Transcriptomic analysis of PI3K/mTOR pathway. 
Looking for a possible correlation between RICTOR gene dosage and 
transcriptional output of PI3K/mTOR pathway, in our cohort we found a trend for 
a positive correlation between the PI3K signature and high gain of RICTOR (Figure 
11A). In keeping with this, we found an inverse correlation between high gain of 
RICTOR and a signature of negative regulators of the pathway, which might suggest 
increased pathway activity (Figure 11B). 
Figure 11. Transcriptional signatures of PI3K/mTOR activation in SQLC. Higher 
levels of the PI3K signature (lPMID Creighton) in RICTOR high gain cases (HG, 
n=2) compared to RICTOR low gain (LG, n=10) and RICTOR wild-type (WT, 
n=26) [A]. Lower levels of the “Negative regulation of the PI3K AKT Network” 
signature in RICTOR high gain cases (HG, n=2) compared to RICTOR low gain 
(LG, n=10) and RICTOR wild-type (WT, n=26) [B]. Box plot represents the lower, 
median and upper quartile, while whiskers represent the highest and the lowest 
range for the upper and lower quartiles. 
 
The mTOR pathway analysis was further performed subdividing the interacting 
partners in five blocks (Figure 12): i) activators/repressors of mTORC1; ii) 
exclusive partners of mTORC1; iii) common partners of mTORC1 and mTORC2; 
iv) exclusive partners of mTORC2; v) RICTOR interacting factors.   
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Figure 12. Gene expression levels of upstream activators/repressors of mTORC1 
[A], exclusive partners of mTORC1 complex [B], common partners of mTORC1 
and mTORC2 complex [C], exclusive partners of mTORC2 complex [D], exclusive 
partners of RICTOR outside of the mTORC2 complex [E]. Transcript levels are 
expressed as normalized counts per million. 
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DISCUSSION 
In the era of cancer molecular profiling, the design and application of risk models 
based on clinical parameters still provides valuable information for clinicians. 
Moreover, the abundance of genomic analyses did not always translate into a 
clinically meaningful result. Therefore, the most promising approach is likely to be 
represented by an integration of clinical data and genomic-proteomic 
characterization. The results of this study support the strength of an integrative 
approach, extending from prognostic dichotomization to multi-platform 
genomic/transcriptomic analyses, able to unravel candidate aberrations with a 
biological impact on SQLC oncogenesis.  
The most intriguing finding we obtained concerns the validation of the 
PI3K/mTORC2-RICTOR axis as a crucial signalling pathway for SQLC in term of 
prevalence and druggable potential. In this regard, we observed alterations in genes 
involved in the mTOR pathway in 42% of training set samples, consistent with the 
reported 47% by TGCA [10]. Although after dichotomizing the patients in 
prognostic subgroups no significant correlations with molecular alterations 
emerged, interestingly PI3KCA mutations and RICTOR high gain were detected 
only in PP group. These observations, together with emerging evidence suggesting 
the interpretation of PI3K/mTOR pathway not only as a unique entity but 
partitioning it into its distinct mTORC1/2-defining subunits and interactors, led our 
study towards a deeper investigation of mTOR pathway [41]. In contrast with 
mTORC1, the mTORC2 still represents a structure with multiple unexplored 
aspects that require convincing answers. Among its components, RICTOR has an 
indispensable role with constantly increasing data implicating its aberrant 
overexpression across numerous cancer types [42]. The molecular analysis of 
overall training set identified RICTOR copy number gain in 23.3%, similarly to 
TGCA (16%)., Furthermore, the transcriptome analysis suggested that RICTOR 
high gain patients presented an increased PI3K/mTOR pathway activity, reinforcing 
the oncogenic background of RICTOR. The identification and validation of a 
reliable biomarker mirroring clinically meaningful PI3K/mTOR/Akt inhibition 
represents a compulsory aim in lung cancer. However, clinical trials exploring the 
efficacy of numerous PI3K/mTOR inhibitors did not conclude to solid benefit, 
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particularly in the context of unselected patients [43]. With this final aim, based on 
our molecular and transcriptomic findings, we designed a series of preclinical 
studies based on RICTOR-amplified SQLC in vitro models that are currently 
ongoing.  
Dealing with prognosis, it has to be considered that the prognostic impact of a 
biomarker is not always associated with its predictive value. Exemplificative the 
case of ERCC1 in lung cancer, where a high ERCC1 expression is associated with 
an improved survival, but a worst outcome after cisplatin-based adjuvant 
chemotherapy [44]. Focusing on the two molecular alterations that stratified 
according to prognosis, DDR2 mutations were detected in 5% of our cohort, 
similarly with what was previously described [45]. Of interest, while to date no 
correlation between DDR2 mutations and survival has been reported [46], we 
observed a significant trend for improved survival in DDR2 mutant patients, all 
belonging to GP group. By contrary, SMAD4 loss was statistically significantly 
associated with a worse prognosis (33.3% in PP versus 7.4% in GP) and this is the 
first evidence in lung cancer, in line with other diseases where this alteration was 
more widely explored [47]. In light of the suggested increased sensitivity to DNA 
topoisomerase inhibitors in lung cancer, this prognostic implication is highly 
intriguing for further investigations [48].  
In the era of immunotherapy, TMB represents a candidate predictive biomarker. Our 
preliminary findings generated by NGS, described a higher TMB in GP than in PP 
group, contributing to enrich the prognostic speculations that are still debatable [49, 
50].   
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CONCLUSION 
In conclusions, our multi-step genomic analysis performed in almost 100 samples 
allowed to obtain a representative picture of SQLC molecular status according to 
patients’ prognosis and to identify altered pathways with a biological impact in 
SQLC oncogenesis, as the PI3K/mTORC2-RICTOR axis. Planning to explore the 
potential role of RICTOR as a predictive biomarker in the context of in vitro and in 
vivo studies and early clinical trial, the existence of an extensive cross talk and 
concomitant aberrations in other genetic loci (KRAS, BRAF) in patients with 
PI3K/mTOR alterations needs to be considered. In fact, in clinical setting this factor 
might sabotage the monotherapy targeting through feedback loops, proposing the 
idea of a combinatorial treatment approach.  
The introduction and validation of a personalized approach in the context of SQLC 
might allow the clinicians to provide the best available therapy for every individual 
patient to potentiate the expected clinical benefit and reduce the human and 
economic cost resulting from a less efficacious not-targeted treatment.  
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